The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05181137
Recruitment Status : Recruiting
First Posted : January 6, 2022
Last Update Posted : September 5, 2023
Sponsor:
Information provided by (Responsible Party):
Reistone Biopharma Company Limited

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 368 subjects aged 18 to 75 years old with Moderately to Severely Active Ulcerative Colitis.

Condition or disease Intervention/treatment Phase
Ulcerative Colitis Drug: SHR0302 Drug: Placebo Phase 3

Detailed Description:
This study consists of a screening period followed by a placebo-controlled Part 1 phase and then a placebo-controlled Part 2 phase. An open label Part 3 phase is open to subjects who: complete the Part 2, are considered non-responders following the Part 1, or have disease worsening during Part 2.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 368 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Study to Evaluate the Efficacy and Long-term Safety of SHR0302 Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Actual Study Start Date : November 5, 2021
Estimated Primary Completion Date : October 31, 2024
Estimated Study Completion Date : March 31, 2025

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Part 1 Active Experimental: SHR0302 Dose#1
SHR0302 Oral tablets taken once daily (QD) for 8 weeks SHR0302 Oral tablets taken once daily (QD)
 Drug: SHR0302
Oral tablets taken once daily (QD)
Placebo Comparator: Part 1 Placebo Comparator: Placebo
Placebo Oral tablets taken once daily (QD) for 8 weeks
 Drug: Placebo
Oral tablets taken once daily (QD)
Experimental: Part 2 Active Experimental: SHR0302 Dose#2
SHR0302 Oral tablets taken once daily (QD) for 44 weeks
 Drug: SHR0302
Oral tablets taken once daily (QD)
Placebo Comparator: Part 2 Placebo Comparator: Placebo
Placebo Comparator: Maintenance Treatment Placebo Comparator: Placebo
 Drug: Placebo
Oral tablets taken once daily (QD)
Experimental: Part 3 Active Experimental: SHR0302 Dose#2
SHR0302 Oral tablets taken once daily (QD) for 26 weeks
 Drug: SHR0302
Oral tablets taken once daily (QD)


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Clinical remission at week 8 (Part 1) [ Time Frame: 8 weeks ]
    The percentage of subjects in clinical remission at week 8.

  2. Clinical remission at week 52 (Part 2) [ Time Frame: 52 weeks ]
    The percentage of subjects in clinical remission at week 52.


Secondary Outcome Measures :
  1. Endoscopic remission at week 8 (Part 1) [ Time Frame: 8 weeks ]
    The percentage of subjects with endoscopic remission at week 8.

  2. Clinical response at week 8 (Part 1) [ Time Frame: 8 weeks ]
    The percentage of subjects with clinical response at week 8.

  3. Change from baseline in partial Mayo score at week 2, 4, and 8 (Part 1) [ Time Frame: 8 weeks ]
    Change from baseline in partial Mayo score at week 2, 4, and 8.

  4. Change in total Mayo score and 9-point modified Mayo score at week 8 (Part 1) [ Time Frame: 8 weeks ]
    Change in total Mayo score and 9-point modified Mayo score at week 8.

  5. Subjects with endoscopic remission (Part 2) [ Time Frame: 52 weeks ]
    The percentage of subjects with endoscopic remission at week 52.

  6. Subjects with clinical response at week 52 (Part 2) [ Time Frame: 52 weeks ]
    The percentage of subjects with clinical response at week 52.

  7. Change from baseline in partial Mayo score at week 12, 16, 24, 32, 40, and 52 (Part 2) [ Time Frame: 52 weeks ]
    Change from baseline in partial Mayo score at week 12, 16, 24, 32, 40, and 52.

  8. Change in total Mayo score and 9-point modified Mayo score at week 52 (Part 2) [ Time Frame: 52 weeks ]
    Change in total Mayo score and 9-point modified Mayo score at week 52.

  9. Subjects in corticosteroid-free remission at week 52 (Part 2) [ Time Frame: 52 weeks ]
    Percentage of subjects in corticosteroid-free remission at week 52.

  10. Subjects who maintain clinical remission at week 52 (Part 2) [ Time Frame: 52 weeks ]
    Percentage of subjects who maintain clinical remission at week 52

  11. Subjects in clinical remission per partial Mayo score at week E26 (Part 3) [ Time Frame: 26 weeks (extension) ]
    The percentage of subjects in clinical remission per partial Mayo score at week E26.

  12. Subjects in corticosteroid-free remission per Partial Mayo score at week E26 (Part 3) [ Time Frame: 26 weeks (extension) ]
    The percentage of subjects in corticosteroid-free remission per Partial Mayo score at week E26.

  13. Change from baseline in Partial Mayo score at week E2, E12, and E26 (Part 3) [ Time Frame: 26 weeks (extension) ]
    Change from baseline in Partial Mayo score at week E2, E12, and E26.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Inclusion Criteria for Part 1

  1. Male or female subjects must be at least at ≥18 and ≤75 years of age
  2. Subject has at least a three-month history of Ulcerative Colitis diagnosis at baseline.
  3. Subject has active Ulcerative Colitis with a 9-point modified Mayo score of ≥ 5 at baseline, with an endoscopic subscore of ≥ 2
  4. Subject is deemed by the physician as having inadequate response, loss of response or intolerance to at least one conventional treatment (oral 5-ASA, immunosuppressants or corticosteroids), or was previously exposed to anti-TNF therapy (e.g., infliximab, adalimumab) or other biological treatment (e.g., vedolizumab) having

Discontinued the treatment for:

  • Infliximab: a minimum of 8 weeks prior to baseline.
  • Adalimumab: a minimum of 10 weeks prior to baseline.
  • Ustekinumab: a minimum of 14 weeks prior to baseline.
  • Vedolizumab: a minimum of 17 weeks prior to baseline.

Inclusion Criteria for Part 2 1. Subject has completed Part 1 and achieved clinical response at week 8

Inclusion Criteria for Part 3

1. Subject has completed the 8-week Part 1 and was classified as not meeting clinical response criteria. OR Subject has discontinued treatment early in the Maintenance phase due to disease worsening OR Subject has completed the Maintenance phase.

Study Exclusion Criteria for Part 1

Exclusion Criteria:

  1. Subject has a diagnosis of indeterminate colitis, or clinical findings suggestive of Crohn'sDisease.
  2. Subject with Ulcerative Colitis, which is confined to a proctitis (distal 15 cm or less).
  3. Treatment naïve subject diagnosed with Ulcerative Colitis (without previous exposure to any of the following therapies for UC treatment: oral 5-ASA, corticosteroids, immunosuppressants, or biological treatments).
  4. Subject is displaying clinical signs of ischemic colitis, fulminant colitis or toxic megacolon.
  5. Subject had previous surgery as a treatment for Ulcerative Colitis or likely to require surgery during the study period.
  6. Subject has evidence of pathogenic bowel infection. Subjects had Clostridium difficile or other intestinal infection within 30 days of screening endoscopy or test positive at screening for C.difficile toxin or other intestinal pathogens.
  7. Subject currently has or has a history of active tuberculosis (TB) or latent TB infection.

  8. Subject is receiving any of the following therapies:

    • Azathioprine/6-mercaptopurine, methotrexate, thalidomide within 7 days prior to baseline.
    • Cyclosporine, mycophenolate, tacrolimus within 4 weeks prior to baseline.
    • Interferon therapy within 8 weeks prior to baseline.
    • Intravenous corticosteroids or rectally administered formulation of corticosteroids or 5- ASA within 2 weeks prior to baseline.
  9. Subject had any prior treatment with lymphocyte-depleting agents/therapies (such as CamPath® [alemtuzumab], alkylating agents [e.g., cyclophosphamide or chlorambucil], total lymphoid irradiation, etc.). Subjects who have received rituximab or other selective B lymphocyte depleting agents are eligible if they have not received such therapy for at least 1 year prior to baseline.
  10. Subject has previously received JAK inhibitors, such as tofacitinib, baricitinib, upadacitinib, filgotinib.
  11. Subject with evidence of clinically relevant laboratory abnormalities which may affect subject safety or interpretation of study results at screening
  12. Subject has a screening 12-lead ECG that demonstrates clinically relevant abnormalities

  13. Subject currently has or had:

    • A clinically significant infection within 1 month of baseline (e.g., those requiring hospitalization or parenteral antimicrobial therapy or have opportunistic infections).
    • A history of more than one episode of herpes zoster, or disseminated zoster (single episode).
    • Any infection otherwise judged by the investigator to have the potential for exacerbation by participation in the study.
    • Any infection requiring antimicrobial therapy within 2 weeks of screening.
  14. Subject has current immunization with any live virus vaccine or history of immunization with any live virus vaccine within 8 weeks of baseline.
  15. Subject with a first-degree relative with a hereditary immunodeficiency.
  16. Subject with a history of any lymphoproliferative disorder (such as EBV-related lymphoproliferative disorder, as reported in some subjects on other immunosuppressive drugs), history of lymphoma, leukemia, multiple myeloma, or signs and symptoms that are suggestive of current lymphatic disease.
  17. Subject has any condition possibly affecting oral drug absorption e.g., gastrectomy, or clinically significant diabetic gastroenteropathy, or certain types of bariatric surgery such as gastric bypass. (Procedures such as gastric banding, gastric balloon that simply divide stomach into separate chambers, are NOT exclusionary.) Subject has undergone significant trauma or major surgery within 4 weeks of baseline.
  18. Women who are pregnant or lactating, or planning pregnancy while enrolled in the study. Male who plan to donate sperm during the study and within 30 days after the last dose of study drug.
  19. Subject who has a history of alcohol or drug abuse with less than 6 months of abstinence prior to baseline that in the opinion of the investigator will preclude participation in the study.
  20. Subject with malignancies or with a history of malignancies with exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin.
  21. Subject infected with human immunodeficiency virus (HIV) or hepatitis B or C viruses.
  22. Subject has received any investigational drug or device within 3 months, or 5 half-lives (if known) prior to baseline.
  23. Subject is receiving or expected to receive prohibited concomitant medication(s) in the 4 weeks prior to the first dose of study drug and through follow-up visit.
  24. Any other condition which in the opinion of the investigator would make the subject unsuitable for inclusion in the study.
  25. Subject with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease), or hematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
  26. Subject with a history of thromboembolic events, including deep vein thromboses (DVT), pulmonary embolism (PE), and those with known inherited conditions that predispose to hypercoagulability.

Study Exclusion Criteria for Parts 2 and 3

  1. Subject with any clinically significant condition at the end of 8-week Induction treatment from Part 1 Induction phase, and Part 2 Maintenance Phase that in the opinion of investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis.
  2. Subject who, in the opinion of the investigator or sponsor, is unlikely to be cooperative or able to comply with study procedures, or any other condition which in the opinion of the investigator would make the subject unsuitable for inclusion.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05181137


Contacts
Layout table for location contacts
Contact: Minna Sun +86 18611785877 minna.sun@reistonebio.com
Contact: Lingyu Guo +86 13311061570 lingyu.guo@reistonebio.com

Locations
Show Show 113 study locations
Sponsors and Collaborators
Reistone Biopharma Company Limited
Investigators
Layout table for investigator information
Study Director: Xiang Chen Reistone Pharma
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Reistone Biopharma Company Limited
ClinicalTrials.gov Identifier: NCT05181137    
Other Study ID Numbers: RSJ10135
First Posted: January 6, 2022    Key Record Dates
Last Update Posted: September 5, 2023
Last Verified: September 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Colitis
Colitis, Ulcerative
Ulcer
Gastroenteritis
Gastrointestinal Diseases
 Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases